New Approach to Phospholipidosis Prediction

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 2R44FD004052-02
Agency Tracking Number: R44FD004052
Amount: $875,580.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: FDA
Solicitation Number: PA13-234
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-09-01
Award End Date (Contract End Date): 2016-08-31
Small Business Information
675 ARAPEEN DRIVE, SUITE 302, Salt Lake City, UT, 84108-1228
DUNS: 179151188
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 FOKVUN CHAN
 (801) 588-0455
 ksauder@echelon-inc.com
Business Contact
 KELLY SAUDER
Phone: (801) 588-0455
Email: ksauder@echelon-inc.com
Research Institution
N/A
Abstract
DESCRIPTION provided by applicant Drug safety is a major concern for pharmaceutical groups regulatory bodies basic researchers and particularly patients Safe and effective drugs maximize successful clinical outcomes and patient compliance This project will provide unique tools for detecting drugs that have potential to induce the dangerous outcome phospholipidosis early in the drug development process and will identify patients that may be susceptible to this dangerous adverse event PUBLIC HEALTH RELEVANCE Drug safety is a major concern for patients taking medicines as well as pharmaceutical companies regulatory bodies and basic researchers Drug induced phospholipidosis DIPL is an adverse reaction to cationic amphiphilic drugs CADs resulting in excessive phospholipid accumulation a condition called phospolipidosis PL which in serious cases leads to organ failure and death The occurrence of DIPL is prevalent reflected by amiodarone a commonly used anti arrythmic drug Approximately of patients prescribed amiodarone will develop DIPL requiring of those affected to cease treatment Amiodarone is representative of CADs which make up a significant fraction of both approved drugs and chemical compounds currently in various phases of pre clinical development While tools are available for screening of many potential adverse events such as cytochrome P and hERG channel inhibition PL inducing potential of drug candidates is hindered by laborious low throughput methods that have been judged unsatisfactory by the FDA This is especially problematic for those cases where only CADs are available as therapeutic options Lysosomal phospholipase A LPLA is a phospholipid processing enzyme central to DIPL Inhibition of LPLA activity induces PL in cells yet an enzymatic assay that would enable high throughput screening HTS of candidate compounds was unavailable until the completion of the Phase I portion of this project The result of the successful Phase I component of this project was development of an HTS assay that successfully identified of known PL inducing drugs as inhibitors of LPLA using purified enzyme This Phase II application will adapt the assay developed in Phase I to enable evaluation of LPLA levels and activity in biological samples to establish levels of each that are indicative of healthy and diseased patients data that is heretofore unavailable given the lack of tools When these levels are established patient samples will be screened for PL susceptibility using samples from ongoing clinical studies At the conclusion of this project levels and activity of LPLA associated with diseased states will be established for the first time in addition to the development and release of new products that will have the ability to serve as companion diagnostics to identify patients that are susceptible t PL and as tools to screen for PL inducing potential of drug candidates early on the discovery process ultimately leading to decreased drug costs and improved patient outcomes With approximately one third of all drugs entering clinical trials failing because of toxicity and safet concerns early detection of DIPL would decrease health care costs by identifying drugs that will induce DIPL prior to expensive clinical trials The specific application to personalized medicine will identify individuals who are susceptible to DIPL for a given drug and guide treatment thereby preventing patient harm and improving the efficiency of healthcare in the U S

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government